recombinant lymphocytic choriomeningitis virus -based vaccine vector expressing TRP2 (HOOKIPA Pharma)

N/A

Report date: 2025/01/26 17:44:03

Base Information

Drug Namerecombinant lymphocytic choriomeningitis virus -based vaccine vector expressing TRP2 (HOOKIPA Pharma)

Drug Alias NameArenavirus Vector-Based Immunotherapy (HOOKIPA Pharma)artLCMV-TRP2 (HOOKIPA Pharma)

ClassificationBiologics

Mechanisms of ActionMacrophage migration inhibitory factor modulators

TargetsMacrophage migration inhibitory factor

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustria

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHookipa Pharma Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsMelanoma

Inactive IndicationsN/A

ATC CodeN/A